Comparisons of clinical characteristics and prognosis between patients with primary and secondary thyroid lymphoma
10.3760/cma.j.issn.0253-2727.2019.07.006
- VernacularTitle: 原发与继发甲状腺淋巴瘤的临床特征和预后比较
- Author:
Rui SUN
1
;
Qing SHI
;
Rong SHEN
;
Ying QIAN
;
Pengpeng XU
;
Shu CHEN
;
Li WANG
;
Weili ZHAO
Author Information
1. Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, State Key Laboratory of Medical Genomics, Shanghai 200025, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, non-Hodgkin;
Thyroid neoplasms;
Disease attribute;
Prognosis
- From:
Chinese Journal of Hematology
2019;40(7):568-572
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare clinical characteristics and prognosis between patients with primary (PTL) and secondary thyroid lymphoma (STL) .
Methods:A retrospective analysis was performed on 46 patients with thyroid lymphoma (PTL 19, STL 27) from January 2002 to October 2018.
Results:①PTL group included 4 males and 15 females, with a median age of 57 years. The STL group included 10 males and 17 females, with a median age of 61 years. Diffuse large B-cell lymphoma (DLBCL) was the main pathological subtype in both PTL and STL groups, with 14 cases (73.7%) and 20 cases (74.1%) respectively. In terms of clinical manifestations, goiter was the most common symptom in PTL patients 100.0% (19/19) , while 29.6% (8/27) STL had goiter (P<0.001) . The incidences of increased thyroglobulin antibody (TRAb) /thyroid peroxidase antibody (TPO) were 81.3% (13/16) in PTL group and 43.8% (7/16) in STL group (P=0.028) respectively. Concerning the clinical features of patients, only two PTL patients (10.5%) with advanced Ann Arbor stage (Ⅲ/Ⅳ) , while 21 (77.8%) STL experienced advanced Ann Arbor stage (P<0.001) . Elevated serum β2-MG were appeared in 1 (7.1%) PTL and 9 (47.4%) STL patients (P=0.013) , and advanced IPI score (3-5) was more common in STL than PTL (59.3% vs 5.3%, P<0.001) . ②Among the 17 PTL patients who received treatments, 15 (88.2%) achieved remission; as for STL patients received treatments, 23/25 (92.0%) were in remission. The 5-year overall survival (OS) rates of PTL (n=17) and STL groups (n=25) were (87.4±8.4) % and (70.0±13.1) % (P=0.433) respectively. ③The 5-year OS rate in 41 patients with B-cell thyroid lymphoma was (81.1±7.5) %. Univariate analysis showed that IPI score of 3-5 (P=0.040) and high level of serum IL-8 (P=0.022) were significantly associated with poor outcome.
Conclusion:DLBCL was the most common subtype in both PTL and STL, and goiter was the major symptom in PTL. IPI score of 3-5 and high level of serum IL-8 were unfavorable prognostic factors for patients with B-cell thyroid lymphoma.
